Alerts will be sent to your verified email
Verify Email
ASTONEALAB
|
Astonea Labs
|
Beta Drugs
|
|
|---|---|---|
|
Operational Metrics
|
||
|
Financials
|
||
|
5 yr Average ROE
|
18.71 % | 22.74 % |
|
5yr average Equity Multiplier
|
6.86 | 1.82 |
|
5yr Average Asset Turnover Ratio
|
0.89 | 1.03 |
|
5yr Avg Net Profit Margin
|
3.1 % | 12.23 % |
|
Price to Book
|
8.58 | 8.55 |
|
P/E
|
29.47 | 39.75 |
|
5yr Avg Cash Conversion Cycle
|
85.07 Days | 7.75 Days |
|
Inventory Days
|
86.76 Days | 46.07 Days |
|
Days Receivable
|
118.45 Days | 91.57 Days |
|
Days Payable
|
163.78 Days | 119.03 Days |
|
5yr Average Interest Coverage Ratio
|
2.12 | 14.42 |
|
5yr Avg ROCE
|
18.06 % | 27.84 % |
|
5yr Avg Operating Profit Margin
|
15.14 % | 21.76 % |
|
5 yr average Debt to Equity
|
3.71 | 0.29 |
|
5yr CAGR Net Profit
|
84.54 % | 29.34 % |
|
5yr Average Return on Assets
|
2.92 % | 12.69 % |
|
Shareholdings
|
||
|
Promoter Holding
|
72.3 % | 66.73 % |
|
Share Pledged by Promoters
|
0.0 | 0.0 |
|
Change in Promoter Holding (3 Yrs)
|
0.0 | 0.02 % |
|
Change in Mutual Fund Holding (3 Yrs)
|
0.0 | 0.0 |
|
Astonea Labs
|
Beta Drugs
|
|
|---|---|---|
|
Product Wise Break-Up
|
Product Wise Break-Up
|
Product Wise Break-Up
|